Kristen Fortney discusses the Bioage platform and one of their most promising drugs. Bioage focuses on translating and analyzing human-derived molecular data to discover drug candidates that have already have clinical data and partial approval. Doing so allows them to rapidly bring drugs to market and focus on drugs which have the highest chance of affecting aging in humans.
The Bioage platform has 1.5 million clinical data points and 64 million molecular data points, leading to roughly 20 pathways assessed each year. Out of their data funnel, three clinical stage assets have emerged. Their most promising candidate is BGE-175.
BGE-175 is a drug which has partial approval (up to phase 3) and helps prevent immunosenescence. This drug could help slow aging while also protecting people against COVID and other related viruses.